1,500
Participants
Start Date
March 1, 2018
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Hydralazine Isosorbide Dinitrate
Tablet BiDil (Hydralazine 37.5 mg/ Isosorbide Dinitrate (ISDN) 20 mg) 2 tablets x 3 daily
Placebo Oral Tablet
2 tablets x 3 daily
Metformin Hydrochloride
Tablet Metformin hydrochloride 500 mg 2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
Placebo Oral Tablet
2 tablets x 2 daily (eGFR 35-60 ml/min: 500 mg x 2 daily)
RECRUITING
Holbæk Hospital, Holbæk
RECRUITING
Sygehus Sønderjylland, Aabenraa, Aabenraa
RECRUITING
Aalborg University Hospital, Aalborg
RECRUITING
Aarhus University Hospital, Aarhus
RECRUITING
Amager Hospital, Copenhagen
RECRUITING
Bispebjerg Hospital, Copenhagen
RECRUITING
Gentofte Hospital, Copenhagen
RECRUITING
Glostrup Hospital, Copenhagen
RECRUITING
Herlev Hospital, Copenhagen
RECRUITING
Hvidovre Hospital, Copenhagen
RECRUITING
Rigshospitalet, Copenhagen
RECRUITING
Sydvestjysk Sygehus, Esbjerg, Esbjerg
RECRUITING
Herning Hospital, Herning
RECRUITING
Nordsjællands Hospital Hillerød, Hillerød
RECRUITING
Regionshospital Nordjylland, Hjørring, Hjørring
RECRUITING
Holbæk Hospital, Holbæk
RECRUITING
Horsens Hospital, Horsens
RECRUITING
Kolding Hospital, Kolding
NOT_YET_RECRUITING
Nykøbing Falster Hospital, Nykøbing Falster
RECRUITING
Odense University Hospital, Odense
RECRUITING
Randers Hospital, Randers
RECRUITING
Sjællands Universitetshospital, Roskilde, Roskilde
TERMINATED
Silkeborg Hospital, Silkeborg
RECRUITING
Slagelse Sygehus, Slagelse
RECRUITING
Vejle Hospital, Vejle
RECRUITING
Viborg Hospital, Viborg
Collaborators (1)
Danish Heart Foundation
OTHER
Danish Council for Independent Research
OTHER
The Danish Regions: Foundation for Medical Research
UNKNOWN
The Novo Nordisk Foundation
UNKNOWN
The Aase og Ejnar Danielsen Foundation
UNKNOWN
Henrik Wiggers
OTHER